5-Ethynyl-l-o-D-ribofuranosylimidazole-4-carboxamide (EICAR) and 6'-(R)-6'-C-methylneplanocin A (TJ13025) are two novel antiviral agents which are targeted against IMP dehydrogenase and S-adenosylhomocysteine hydrolase, respectively. These compounds have been examined for their activities against various strains of orthomyxoviruses (influenza virus) and paramyxoviruses (parainfluenza virus, mumps virus, measles virus, and respiratory syncytial virus) in vitro. EICAR was 10-to 59-fold more active than ribavirin and TJ13025 was 32-to 330-fold more active than ribavirin against parainfluenza virus (types 2 and 3), mumps virus, and measles virus. EICAR was also more active than ribavirin against respiratory syncytial virus and influenza virus, whereas TJ13025 was virtually inactive against these viruses. The 50% virus-inhibitory concentrations of EICAR and TJ13025 were generally within the 0.1-to 1-,ug/ml range. Although the compounds did not prove cytotoxic to stationary host cells (HeLa, Vero, MDCK, and LLCMK2) at a concentration of 200 ,ug/ml, concentrations of 4 to 13 ,ug/ml inhibited the growth of dividing cells. EICAR and TJ13025 should be further pursued as candidate drugs for the treatment of ortho-and paramyxovirus infections.
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Ribavirin has been licensed for clinical use (as an aerosol) in the treatment of respiratory syncytial virus (RSV) infections. Inhalation of aerosolized ribavirin by infants with RSV pneumonia or college students with influenza A leads to an improvement of the clinical symptoms in these patients (7, 19, 20) . The mechanism of action of ribavirin and its metabolism by cells have been investigated (5, 6, 17, 18, 21) ; the main targets for the antiviral action of ribavirin and its phosphorylated form appear to be IMP dehydrogenase, viral mRNA cap formation, and viral RNA transcriptase or polymerase.
Recently, we have reported two novel nucleoside analogs, 5 -ethynyl -1-, -D -ribofuranosylimidazole -4 -carboxamide (EICAR) and 6'-(R)-6'-C-methylneplanocin A (TJ13025), as broad-spectrum antiviral agents active against a wide variety of pox-, toga-, reo-, myxo-, rhabdo-, and arenaviruses in vitro (3, 16) . In this study, we have evaluated the inhibitory effects of EICAR and TJ13025 in comparison with those of ribavirin on the in vitro replication of several ortho-and paramyxoviruses.
MATERIALS AND METHODS
Compounds. The sources of the three compounds used in this study were TJ13025, Toyo Jozo Research Center, Ohito, Shizuoka, Japan (16) .
Viruses. The origins of the viruses and preparations of the virus stocks have been reported previously (8, 9, 15) . Subtypes, strains, abbreviations, and passage histories of the viruses were as follows. Influenza viruses (FLUV) A/Bangkok/10/83/HlN1, A/Ishikawa/7/82/H3N2, and B/Singapore/222/79 (13) and parainfluenza virus (PFLUV) type 1 (Sendai virus, Fushimi strain) were gifts from N. Ishida, Tohoku University, Sendai, Japan; they were passaged more than 10 times in fertile hen's eggs and 3 times in MDCK cells or LLCMK2 cells respectively. PFLUV type 2 (CA, Greer strain) and type 3 (HA-1, C243 strain) (11) higher than that in ordinary MEM), 100 U of penicillin G per ml, and 100 ,xg of streptomycin per ml. For RSV infection of HeLa cells, we used a maintenance medium (MM) consisting of MEM with 2% heat-inactivated fetal calf serum, a fourfold-increased concentration of L-glutamine, 1.6% glucose, and antibiotics as cited above. Vero, MDCK, and LLCMK2 cells were cultured in MEM plus 10% newborn calf serum and antibiotics. For infection of Vero cells with PFLUV (type 2 or 3), MPSV, or MLSV, MM consisting of MEM with 2% heat-inactivated fetal calf serum and antibiotics was used. For the infection of LLCMK2 cells with PFLUV type 1 and of MDCK cells with FLUV, MM consisting of MEM with 0.2% bovine serum albumin, 2.5 ,ug of crystallized trypsin per ml (Sigma Chemical Co., St. Louis, Mo.), and antibiotics was used.
Antiviral assays. All cell cultures were seeded in 24-well tissue culture plates (Falcon 3407; Becton Dickinson Co., Oxnard, Calif.) at 1.5 x 105 cells per well and incubated at 37°C. After 1 to 2 days of incubation, when the cell cultures became confluent, the growth medium was withdrawn and the cell monolayers were washed once with MM. To each well was added 20 to 40 virus PFU in 0.1 ml of MM. Samples (0.2 ml) of several fourfold dilutions of compounds in MM and 0.7 ml of 1% methylcellulose (Methocel A-4M Premium; Dow Chemical Co., Midland, Mich.) were added to the wells simultaneously with the virus inocula. The infected cell cultures were incubated at 35°C in a CO2 incubator. After 3 to 4 days of incubation, the overlay medium was withdrawn and the cell sheets were stained with a 0.1% neutral red solution in MM for 2 h at 37°C. After the staining, the cell sheets were fixed with 5% formalin in phosphate-buffered saline (pH 7.2) and the plaque numbers were counted under the microscope (magnification, x40). For FLUV and PFLUV type 1, focus formation was monitored by hemadsorption of guinea pig erythrocytes to infected cells at 4°C for 1 h before fixation of the cell sheets. The minimal concentration of compound required to inhibit by 50% the number of plaques or hemadsorbing foci was estimated as the 50% effective concentration (EC50).
Cytotoxicity tests. HeLa, Vero, and MDCK cells in growth medium were seeded at 5 x 104 cells per well in 24-well tissue culture plates (Falcon 3702; Becton Dickinson Co.) and allowed to adhere to the plates for a period of 15 or 36 h at 37°C. The medium was then replaced by fresh medium containing different concentrations of the test compounds. Two sets of experiments were carried out. In the first set, medium was replaced by MM containing compound after 36 h of seeding (when a confluent monolayer had formed) and the cells were further incubated at 35°C. In the second set, the medium was changed with growth medium containing compound after 15 h of seeding (when the monolayer was not yet confluent) and the cells were further incubated at 37°C. Each dilution of compound was added to three wells per cell culture. After 3 days of incubation at 35 or 37°C in 5% C02, the cytotoxicity of each compound was monitored by counting the viable cell numbers with a hemocytometer. The numbers of viable cells were determined by trypan blue exclusion. Cell viability was also examined by the ability of the cells to incorporate 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT). Cells were seeded in 96-well tissue culture trays (Falcon 3402) at 5 x 103 cells per well and allowed to adhere to the plate as in the cell-counting experiment. The precise MTT procedure has been described elsewhere (12) . The cytotoxicity of each compound was expressed as the 50% inhibitory concentration (IC50), which is the minimal concentration required to reduce the number of viable cells to 50% of the control. The selectivity index of each compound was determined as the ratio of the IC50 for cell viability to the EC50 for virus replication.
RESULTS
Inhibitory activities of ribavirin, EICAR, and TJ13025 against several ortho-and paramyxovirus strains. Ribavirin, EICAR, and TJ13025 were examined for their activities against four strains of RSV, three strains each of PFLUV and FLUV, and four strains each of MPSV and MLSV (Table 1) . Ribavirin inhibited the replication of RSV and FLUV at EC50s of 1.38 to 5.3 jig/ml and the replication of PFLUV, MPSV, and MLSV at EC50s of 8.6 to 67 ,ug/ml.
EICAR exhibited a potent inhibitory activity against all viruses (EC50s, 0.06 to 2.3 ,ug/ml). TJ13025 also showed very low EC50s against the paramyxoviruses (0.12 to 0.62 ,ug/ml), except for PFLUV type 1 and RSV, but was inactive against the orthomyxoviruses (EC50, >100 Lg/ml).
From the ratios of the EC50 of ribavirin to the EC50 of EICAR or TJ13025, it appears that EICAR is about 10-to 59-fold more potent than ribavirin against paramyxoviruses and about 2-to 4-fold more potent than ribavirin against FLUV. TJ13025 also showed a 32-to 330-fold-greater potency than ribavirin against all paramyxovirus strains, except for RSV and PFLUV type 1 (Sendai). TJ13025 is at least 20-to 50-fold less active than ribavirin against FLUV.
Cytotoxicities of ribavirin, EICAR, and TJ13025 for HeLa, Vero, MDCK, and LLCMK2 cells. None of the compounds showed cytotoxicity at a concentration of 200 ,ug/ml for any of the cell lines in the stationary phase, whether the viablecell number was assessed by the MTT method or hemocytometer (Table 2 ; the data obtained by the MTT method are not shown). When cytotoxicity measurements were done with replicating cells, EICAR and TJ13025 showed much lower IC50s (based on the reduction in cell counts) of 4.1 to 13.0 and 5.6 to 12.0 ,ug/ml, respectively. Ribavirin also proved cytotoxic to replicating cells, with IC50s ranging from 14 to 69 jig/ml. The corresponding IC50s obtained by the MTT method varied from 6.6 to 80 ,ug/ml (data not shown).
Selectivity indices of ribavirin, EICAR, and TJ13025 for selected strains of ortho-and paramyxoviruses. The selectivity indices of EICAR and TJ13025 (Table 3) against paramyxoviruses (except for RSV) were much higher than those of ribavirin, whether the cells were incubated while stationary or growing, in the cytotoxicity test. However, the differences were much lower when the cells were growing. EICAR showed selectivity indices three to four times higher than those of ribavirin against FLUV against both stationary and growing cells. TJ13025 did not show any positive (>1) selectivity indices against RSV and FLUV.
DISCUSSION
In previous papers (3, 16), we have reported that EICAR and TJ13025 have broad-spectrum antiviral activities against a variety of DNA and RNA viruses. In this study, we demonstrated that both compounds are particularly active against representative paramyxoviruses and that EICAR is also active against orthomyxoviruses. EICAR was 10-to 59-fold more active than ribavirin and TJ13025 was 32-to 330-fold more active than ribavirin against paramyxoviruses.
EICAR can be considered an analog of ribavirin, in which the N in position 2 of the triazole ring has been replaced by a C-cCH group. Accordingly, EICAR has an antiviralactivity spectrum quite similar to that of ribavirin. TJ13025 can be considered a 6'-(R)-methyl-substituted derivative of the methylation reactions (with S-adenosylmethionine as the neplanocin A, which itself corresponds to cyclopentenyladmethyl donor) that are required for maturation of the viral enine. EICAR and ribavirin are assumed to exert their mRNA (2, 4).
antiviral actions primarily through depletion of the intracel-TJ13025 did not prove inhibitory to FLUV replication at lular GTP pool levels, following inhibition of IMP dehydroconcentrations of up to 100 ,ug/ml. Other SAH hydrolase genase activity (3, 18) . On the other hand, neplanocin A is inhibitors, i.e., carbocyclic 3-deazaadenosine, apparently known as a potent inhibitor of S-adenosylhomocysteine fail to block the replication of orthomyxoviruses, despite (SAH) hydrolase (1) . Neplanocin A has broad-spectrum unequivocal evidence of their activities against paramyxoviactivity against a variety of DNA and RNA viruses but is ruses both in vitro and in vivo (4, 16, 22) . The differential also fairly toxic to the host cells (2) . Also, TJ13025 is a behaviors of TJ13025 and other SAH hydrolase inhibitors potent inhibitor of SAH hydrolase (16) and, in addition, has against orthomyxoviruses and paramyxoviruses may be remarked activity against a broad range of DNA and RNA lated to differences in methylation requirements of the orthoviruses (16) . SAH hydrolase inhibitors are assumed to inhibit and paramyxoviral mRNAs. In fact, it has been well estab- Finally, the potent inhibitory effects that have been noted for EICAR against ortho-and paramyxoviruses and for TJ13025 against paramyxoviruses make these compounds attractive candidate drugs for further study of ortho-and paramyxovirus infections.
